| 1 | Clinical characteristics and treatment patterns of patients with NTRK fusion-positive solid tumors: A multisite cohort study at US academic cancer centers. (Willis C, Au T, Hejazi A, Griswold C, Schabath MB, Thompson J, Malhotra J, Federman N, Ko G, Appukkuttan S, Warnock N, Kong SX, Hocum B, Brixner D, Stenehjem D) J Manag Care Spec Pharm 2024 Jul;30(7):672-683 |
| 1 | Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial. (Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Marshall RS, Broderick JP, Aragón García R, Plummer P, Sabagha N, Pauls Q, Cassarly C, Dillon CR, Di Tullio MR, Hod EA, Soliman EZ, Gladstone DJ, Healey JS, Sharma M, Chaturvedi S, Janis LS, Krishnaiah B, Nahab F, Kasner SE, Stanton RJ, Kleindorfer DO, Starr M, Winder TR, Clark WM, Miller BR, Elkind MSV, ARCADIA Investigators) JAMA 2024 Feb 20;331(7):573-581 20 Citations |
| 1 | Efficacy and Risk Stratification of Janus Kinase Inhibitors in the Treatment of Moderate-to-Severe Atopic Dermatitis. (Narla S, Silverberg JI) Dermatitis 2024;35(S1):S24-S38 1 Citation |
| 1 | An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. (Reyes Gaido OE, Pavlaki N, Granger JM, Mesubi OO, Liu B, Lin BL, Long A, Walker D, Mayourian J, Schole KL, Terrillion CE, Nkashama LJ, Hulsurkar MM, Dorn LE, Ferrero KM, Huganir RL, Müller FU, Wehrens XHT, Liu JO, Luczak ED, Bezzerides VJ, Anderson ME) Sci Transl Med 2023 Jun 21;15(701):eabq7839 5 Citations |
| 1 | A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. (Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S) Target Oncol 2023 Jul;18(4):517-530 7 Citations |
| 1 | Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. (Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA) Clin Cancer Res 2022 Aug 02;28(15):3242-3247 15 Citations |
| 1 | Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. (Schroeder MA, Hari PN, Blithe A, Paranagama D, Bhatt V, DiPersio JF) Bone Marrow Transplant 2022 Jun;57(6):975-981 4 Citations |
| 1 | Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. (Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B, ARASENS Trial Investigators) N Engl J Med 2022 Mar 24;386(12):1132-1142 390 Citations |
| 1 | Glucocorticoid Receptor Antagonist Alters Corticosterone and Receptor-sensitive mRNAs in the Hypoxic Neonatal Rat. (Gehrand AL, Phillips J, Welhouse KD, Siddiqui H, Schulgit M, Hoffman J, Hunt H, Raff H) Endocrinology 2022 Jan 01;163(1) 3 Citations |
| 1 | Avapritinib in the Treatment of Systemic Mastocytosis: an Update. (Below S, Michaelis LC) Curr Hematol Malig Rep 2021 Oct;16(5):464-472 4 Citations |
| 1 | Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. (Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW, COV-BARRIER Study Group) Lancet Respir Med 2021 Dec;9(12):1407-1418 477 Citations |
| 1 | Idiopathic multicentric Castleman disease with TAFRO clinical subtype responsive to IL-6/JAK inhibition: A pediatric case series. (Lust H, Gong S, Remiker A, Rossoff J) Pediatr Blood Cancer 2021 Oct;68(10):e29261 11 Citations |
| 2 | Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. (Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M) Br J Haematol 2021 Nov;195(3):429-432 6 Citations |
| 1 | Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. (Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M) Lancet 2021 Mar 06;397(10277):892-901 281 Citations |
| 2 | Peripherally restricted cannabinoid type 1 receptor (CB1R) antagonist, AM6545, potentiates stress-induced hypothalamic-pituitary-adrenal axis activation via a non-CB1R mechanism. (Roberts CJ, Hillard CJ) Endocrine 2021 Apr;72(1):297-300 2 Citations |
| 1 | Successful management of SARS-CoV-2 acute respiratory distress syndrome and newly diagnosed acute lymphoblastic leukemia. (Phillips L, Pavisic J, Kaur D, Dorrello NV, Broglie L, Hijiya N) Blood Adv 2020 Sep 22;4(18):4358-4361 13 Citations |
| 1 | Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. (Putman M, Chock YPE, Tam H, Kim AHJ, Sattui SE, Berenbaum F, Danila MI, Korsten P, Sanchez-Alvarez C, Sparks JA, Coates LC, Palmerlee C, Peirce A, Jayatilleke A, Johnson SR, Kilian A, Liew J, Prokop LJ, Murad MH, Grainger R, Wallace ZS, Duarte-García A, COVID-19 Global Rheumatology Alliance) Arthritis Rheumatol 2021 Jan;73(1):36-47 49 Citations |
| 1 | The prognostic utility of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease: The largest cohort to date. (Kolkailah AA, Iskander M, Iskander F, Patel PP, Khan R, Doukky R) J Nucl Cardiol 2022 Feb;29(1):101-110 12 Citations |
| 1 | A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. (Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, Tracy M, Freshwater T, Lee MA, Liu J, Qiu J, Rose S, Rubin EH, Moore K) Clin Cancer Res 2020 Sep 15;26(18):4767-4776 70 Citations |
| 1 | The prognostic value of regadenoson SPECT myocardial perfusion imaging: The largest cohort to date. (Kattoor AJ, Kolkailah AA, Iskander F, Iskander M, Diep L, Khan R, Doukky R) J Nucl Cardiol 2021 Dec;28(6):2799-2807 11 Citations |
| 2 | Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease. (Abedin SM, Hamadani M) Expert Opin Investig Drugs 2020 May;29(5):423-427 7 Citations |
| 1 | Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. (Bromberg JS, Weir MR, Gaber AO, Yamin MA, Goldberg ID, Mayne TJ, Cal W, Cooper M) Transplantation 2021 Feb 01;105(2):443-450 14 Citations |
| 1 | Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. (Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA) Clin Cancer Res 2020 Jul 15;26(14):3589-3596 89 Citations |
| 1 | Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. (Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ) Blood 2020 May 14;135(20):1739-1749 181 Citations |
| 1 | Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. (Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, Means-Powell J, Werner TL, Becerra C, Wang C, Leonowens C, Kalyana-Sundaram S, Kleha JF, Gauvin J, D'Amelio AM Jr, Ellis C, Ibrahim N, Yan L) Cancer Chemother Pharmacol 2020 Apr;85(4):673-683 41 Citations |
| 13 | Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 12 Citations |
| 4 | Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse. (Urrutia G, Salmonson A, Toro-Zapata J, de Assuncao TM, Mathison A, Dusetti N, Iovanna J, Urrutia R, Lomberk G) Mol Cancer Res 2020 Mar;18(3):448-462 11 Citations |
| 1 | Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. (Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S, Gitlin SD, Kaminski M, Cusick A, Phillips T, Sood S, Talpaz M, Quiery A, Boonstra PS, Wilcox RA) Lancet Haematol 2019 Dec;6(12):e630-e637 196 Citations |
| 1 | Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. (Lindner JR, Belcik T, Widlansky M, Harmann LM, Karafin MS, Wandersee NJ, Puligandla M, Neuberg D, Linden J, Field JJ) PLoS One 2019;14(7):e0218783 9 Citations |
| 1 | Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. (Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S) Biol Blood Marrow Transplant 2019 Oct;25(10):2002-2007 65 Citations |
| 1 | Prognostic value of regadenoson stress myocardial perfusion imaging in patients with left bundle branch block or ventricular paced rhythm. (Iskander F, Iskander M, Gomez J, Doukky R) J Nucl Cardiol 2021 Jun;28(3):967-977 6 Citations |
| 7 | Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 Aug;25(8):1689-1694 71 Citations |
| 1 | Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL). (Akhtar OS, Attwood K, Lund I, Hare R, Hernandez-Ilizaliturri FJ, Torka P) Leuk Lymphoma 2019 Jul;60(7):1650-1655 28 Citations |
| 1 | Three-dimensional analysis reveals altered chromatin interaction by enhancer inhibitors harbors TCF7L2-regulated cancer gene signature. (Gerrard DL, Wang Y, Gaddis M, Zhou Y, Wang J, Witt H, Lin S, Farnham PJ, Jin VX, Frietze SE) J Cell Biochem 2019 Mar;120(3):3056-3070 8 Citations |
| 1 | Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity. (Carter RLR, Talbot K, Hur WS, Meixner SC, Van Der Gugten JG, Holmes DT, Côté HCF, Kastrup CJ, Smith TW, Lee AYY, Pryzdial ELG) J Thromb Haemost 2018 Nov;16(11):2276-2288 38 Citations |
| 1 | Is ibrutinib associated with disseminated cryptococcosis with CNS involvement? (Abid MB, Stromich J, Gundacker ND) Cancer Biol Ther 2019;20(2):138-140 8 Citations |
| 1 | Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. (Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C) Am J Hematol 2018 Nov;93(11):1394-1401 56 Citations |
| 1 | Prognostic significance of ischemic electrocardiographic changes with regadenoson stress myocardial perfusion imaging. (Doukky R, Nigatu A, Khan R, Anokwute C, Fughhi I, Ayoub A, Iskander F, Iskander M, Kola S, Sahyouni M, Karavolos K, Hota BN, Gomez J) J Nucl Cardiol 2020 Oct;27(5):1521-1532 17 Citations |
| 1 | How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. (Jaglowski SM, Blazar BR) Blood Adv 2018 Aug 14;2(15):2012-2019 66 Citations |
| 1 | Chronic treatment with URB597 ameliorates post-stress symptoms in a rat model of PTSD. (Fidelman S, Mizrachi Zer-Aviv T, Lange R, Hillard CJ, Akirav I) Eur Neuropsychopharmacol 2018 May;28(5):630-642 49 Citations |
| 1 | Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. (O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE) JAMA Oncol 2018 May 01;4(5):712-716 18 Citations |
| 1 | P300 Acetyltransferase Mediates Stiffness-Induced Activation of Hepatic Stellate Cells Into Tumor-Promoting Myofibroblasts. (Dou C, Liu Z, Tu K, Zhang H, Chen C, Yaqoob U, Wang Y, Wen J, van Deursen J, Sicard D, Tschumperlin D, Zou H, Huang WC, Urrutia R, Shah VH, Kang N) Gastroenterology 2018 Jun;154(8):2209-2221.e14 144 Citations |
| 3 | Stress Promotes Drug Seeking Through Glucocorticoid-Dependent Endocannabinoid Mobilization in the Prelimbic Cortex. (McReynolds JR, Doncheck EM, Li Y, Vranjkovic O, Graf EN, Ogasawara D, Cravatt BF, Baker DA, Liu QS, Hillard CJ, Mantsch JR) Biol Psychiatry 2018 Jul 15;84(2):85-94 42 Citations |
| 1 | Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). (Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, Hamadani M, Ghosh N, Reeder CB, Barnett E, Bravo MC, Martin P) J Hematol Oncol 2017 Nov 02;10(1):171 36 Citations |
| 1 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. (Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, Fehniger TA) Blood 2018 Jan 11;131(2):182-190 114 Citations |
| 1 | Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. (Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S) Blood 2017 Nov 23;130(21):2243-2250 326 Citations |
| 4 | 17β-Estradiol Potentiates the Reinstatement of Cocaine Seeking in Female Rats: Role of the Prelimbic Prefrontal Cortex and Cannabinoid Type-1 Receptors. (Doncheck EM, Urbanik LA, DeBaker MC, Barron LM, Liddiard GT, Tuscher JJ, Frick KM, Hillard CJ, Mantsch JR) Neuropsychopharmacology 2018 Mar;43(4):781-790 33 Citations |
| 1 | BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC) J Clin Oncol 2017 May 01;35(13):1437-1443 365 Citations |
| 1 | The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. (Guinn D, Lehman A, Fabian C, Yu L, Maddocks K, Andritsos LA, Jones JA, Flynn JM, Jaglowski SM, Woyach JA, Byrd JC, Johnson AJ) Cancer Med 2017 Apr;6(4):778-787 14 Citations |
| 1 | AZD1775 induces toxicity through double-stranded DNA breaks independently of chemotherapeutic agents in p53-mutated colorectal cancer cells. (Webster PJ, Littlejohns AT, Gaunt HJ, Prasad KR, Beech DJ, Burke DA) Cell Cycle 2017;16(22):2176-2182 20 Citations |
| 1 | In silico design of novel probes for the atypical opioid receptor MRGPRX2. (Lansu K, Karpiak J, Liu J, Huang XP, McCorvy JD, Kroeze WK, Che T, Nagase H, Carroll FI, Jin J, Shoichet BK, Roth BL) Nat Chem Biol 2017 May;13(5):529-536 211 Citations |
| 4 | Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. (Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabhan C, Costa LJ, Kenkre VP, Hari PN, Fenske TS) Hematol Oncol 2017 Dec;35(4):528-535 59 Citations |
| 1 | Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. (Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB) Blood 2016 Dec 22;128(25):2899-2908 62 Citations |
| 1 | Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. (Kharfan-Dabaja MA, El-Asmar J, Awan FT, Hamadani M, Ayala E) Best Pract Res Clin Haematol 2016 Mar;29(1):54-66 6 Citations |
| 1 | Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. (Hong D, Infante J, Janku F, Jones S, Nguyen LM, Burris H, Naing A, Bauer TM, Piha-Paul S, Johnson FM, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J) J Clin Oncol 2016 May 20;34(15):1764-71 130 Citations |
| 1 | Ibrutinib for treatment of chronic lymphocytic leukemia. (Vela CM, McBride A, Jaglowski SM, Andritsos LA) Am J Health Syst Pharm 2016 Mar 15;73(6):367-75 12 Citations |
| 1 | The Functional Significance of Posttranslational Modifications on Polo-Like Kinase 1 Revealed by Chemical Genetic Complementation. (Lasek AL, McPherson BM, Trueman NG, Burkard ME) PLoS One 2016;11(2):e0150225 9 Citations |
| 5 | Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 18 Citations |
| 1 | Can selectin and iNKT cell therapies meet the needs of people with sickle cell disease? (Field JJ) Hematology Am Soc Hematol Educ Program 2015;2015:426-32 5 Citations |
| 1 | Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress. (Falchook GS, Bastida CC, Kurzrock R) Semin Oncol 2015 Dec;42(6):832-48 85 Citations |
| 1 | Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. (Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J) Leukemia 2016 Jun;30(6):1413-5 6 Citations |
| 2 | CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats. (McReynolds JR, Doncheck EM, Vranjkovic O, Ganzman GS, Baker DA, Hillard CJ, Mantsch JR) Psychopharmacology (Berl) 2016 Jan;233(1):99-109 34 Citations |
| 1 | Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. (Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA) Leukemia 2016 Feb;30(2):346-50 81 Citations |
| 2 | Ibrutinib in Refractory Classic Hodgkin's Lymphoma. (Hamadani M, Balasubramanian S, Hari PN) N Engl J Med 2015 Oct;373(14):1381-2 31 Citations |
| 1 | Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. (Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, Liu C, McDonald DG, Pidala J, Yu XZ) PLoS One 2015;10(9):e0137641 74 Citations |
| 1 | Disruption of peri-adolescent endocannabinoid signaling modulates adult neuroendocrine and behavioral responses to stress in male rats. (Lee TT, Hill MN, Hillard CJ, Gorzalka BB) Neuropharmacology 2015 Dec;99:89-97 20 Citations |
| 1 | Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. (Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA) JAMA Oncol 2015 Apr;1(1):80-7 486 Citations |
| 1 | Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC) Blood 2015 Aug 13;126(7):842-50 117 Citations |
| 1 | Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. (Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ) Blood 2015 Jul 02;126(1):61-8 150 Citations |
| 1 | BDNF interacts with endocannabinoids to regulate cocaine-induced synaptic plasticity in mouse midbrain dopamine neurons. (Zhong P, Liu Y, Hu Y, Wang T, Zhao YP, Liu QS) J Neurosci 2015 Mar 11;35(10):4469-81 33 Citations |
| 1 | Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):214-221.e1 63 Citations |
| 1 | Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. (Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F) Cancer Res 2015 Feb 01;75(3):594-604 68 Citations |
| 2 | Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways. (Baker JE, Su J, Koprowski S, Dhanasekaran A, Aufderheide TP, Gross GJ) J Pharmacol Exp Ther 2015 Mar;352(3):429-37 10 Citations |
| 1 | miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. (Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC) Leukemia 2015 May;29(5):1210-3 17 Citations |
| 1 | A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. (Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA) Blood 2015 Jan 08;125(2):242-8 116 Citations |
| 1 | Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. (Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltsis-Mortari A, Byrd JC, Blazar BR) J Clin Invest 2014 Nov;124(11):4867-76 151 Citations |
| 1 | Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. (Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ) Biomed Res Int 2014;2014:583794 42 Citations |
| 1 | Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? (Barosi G, Zhang MJ, Gale RP) Leukemia 2014 Nov;28(11):2267-70 23 Citations |
| 1 | Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. (Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC) N Engl J Med 2014 Jun 12;370(24):2286-94 1001 Citations |
| 3 | Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. (Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B) Br J Cancer 2014 Jul 08;111(1):85-93 70 Citations |
| 1 | The role of adenosine signaling in sickle cell therapeutics. (Field JJ, Nathan DG, Linden J) Hematol Oncol Clin North Am 2014 Apr;28(2):287-99 23 Citations |
| 3 | Endocannabinoid signaling in hypothalamic-pituitary-adrenocortical axis recovery following stress: effects of indirect agonists and comparison of male and female mice. (Roberts CJ, Stuhr KL, Hutz MJ, Raff H, Hillard CJ) Pharmacol Biochem Behav 2014 Feb;117:17-24 43 Citations |
| 1 | The memory-enhancing effects of hippocampal estrogen receptor activation involve metabotropic glutamate receptor signaling. (Boulware MI, Heisler JD, Frick KM) J Neurosci 2013 Sep 18;33(38):15184-94 163 Citations |
| 1 | Clarifying the use of ruxolitinib in patients with myelofibrosis. (Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO) Oncology (Williston Park) 2013 Jul;27(7):706-14 10 Citations |
| 1 | Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. (Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC) Blood 2013 Oct 10;122(15):2539-49 645 Citations |
| 1 | Eltrombopag-associated hyperpigmentation. (Braunstein I, Wanat KA, Elenitsas R, Xu X, Frey N, Rosenbach M) JAMA Dermatol 2013 Sep;149(9):1112-5 12 Citations |
| 1 | ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK. (Sun Y, Nowak KA, Zaorsky NG, Winchester CL, Dalal K, Giacalone NJ, Liu N, Werner-Wasik M, Wasik MA, Dicker AP, Lu B) Mol Cancer Ther 2013 May;12(5):696-704 53 Citations |
| 1 | RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. (Sun D, Haddad R, Kraniak JM, Horne SD, Tainsky MA) Mol Cancer Res 2013 Jun;11(6):616-27 11 Citations |
| 1 | Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. (Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberg D, Linden J, Nathan DG) Blood 2013 Apr 25;121(17):3329-34 80 Citations |
| 1 | Emerging drugs for myelofibrosis. (Atallah E, Verstovsek S) Expert Opin Emerg Drugs 2012 Dec;17(4):555-70 5 Citations |
| 3 | AMP kinase activation improves angiogenesis in pulmonary artery endothelial cells with in utero pulmonary hypertension. (Teng RJ, Du J, Afolayan AJ, Eis A, Shi Y, Konduri GG) Am J Physiol Lung Cell Mol Physiol 2013 Jan 01;304(1):L29-42 46 Citations |
| 1 | Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching. (Iqbal FM, Hage FG, Ahmed A, Dean PJ, Raslan S, Heo J, Iskandrian AE) JACC Cardiovasc Imaging 2012 Oct;5(10):1014-21 47 Citations |
| 1 | Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. (Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B) Int J Radiat Oncol Biol Phys 2012 Nov 15;84(4):e525-31 20 Citations |
| 1 | Prefrontal cortical anandamide signaling coordinates coping responses to stress through a serotonergic pathway. (McLaughlin RJ, Hill MN, Bambico FR, Stuhr KL, Gobbi G, Hillard CJ, Gorzalka BB) Eur Neuropsychopharmacol 2012 Sep;22(9):664-71 89 Citations |
| 2 | Cannabinoid receptor type 1 (CB1) activation inhibits small GTPase RhoA activity and regulates motility of prostate carcinoma cells. (Nithipatikom K, Gomez-Granados AD, Tang AT, Pfeiffer AW, Williams CL, Campbell WB) Endocrinology 2012 Jan;153(1):29-41 33 Citations |
| 2 | Cannabinoid receptor involvement in stress-induced cocaine reinstatement: potential interaction with noradrenergic pathways. (Vaughn LK, Mantsch JR, Vranjkovic O, Stroh G, Lacourt M, Kreutter M, Hillard CJ) Neuroscience 2012 Mar 01;204:117-24 37 Citations |
| 1 | Extracellular signal-regulated kinase signaling in the ventral tegmental area mediates cocaine-induced synaptic plasticity and rewarding effects. (Pan B, Zhong P, Sun D, Liu QS) J Neurosci 2011 Aug 03;31(31):11244-55 57 Citations |
| 3 | Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. (Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT, Karatsoreos IN, Mackie K, Viau V, Pickel VM, McEwen BS, Liu QS, Gorzalka BB, Hillard CJ) J Neurosci 2011 Jul 20;31(29):10506-15 290 Citations |
| 1 | Pyrazolyl methyls prescribe the electronic properties of iron(II) tetra(pyrazolyl)lutidine chloride complexes. (Morin TJ, Wanniarachchi S, Gwengo C, Makura V, Tatlock HM, Lindeman SV, Bennett B, Long GJ, Grandjean F, Gardinier JR) Dalton Trans 2011 Aug 21;40(31):8024-34 15 Citations |
| 1 | Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. (Gore E, Bae K, Langer C, Extermann M, Movsas B, Okunieff P, Videtic G, Choy H) Clin Lung Cancer 2011 Mar;12(2):125-30 25 Citations |
| 1 | Using sterics to promote reactivity in fac-Re(CO)3 complexes of some 'non-innocent' NNN-pincer ligands. (Wanniarachchi S, Liddle BJ, Toussaint J, Lindeman SV, Bennett B, Gardinier JR) Dalton Trans 2011 Sep 21;40(35):8776-87 19 Citations |
| 1 | Targeting iNKT cells for the treatment of sickle cell disease. (Field JJ, Nathan DG, Linden J) Clin Immunol 2011 Aug;140(2):177-83 38 Citations |
| 1 | Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. (Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC) Blood 2011 Jun 09;117(23):6287-96 674 Citations |
| 3 | Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex. (Ho WS, Patel S, Thompson JR, Roberts CJ, Stuhr KL, Hillard CJ) Br J Pharmacol 2010 Jun;160(3):736-46 10 Citations |
| 1 | Endogenous cannabinoid signaling is essential for stress adaptation. (Hill MN, McLaughlin RJ, Bingham B, Shrestha L, Lee TT, Gray JM, Hillard CJ, Gorzalka BB, Viau V) Proc Natl Acad Sci U S A 2010 May 18;107(20):9406-11 281 Citations |
| 1 | Identification and characterization of the first small molecule inhibitor of MDMX. (Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA) J Biol Chem 2010 Apr 02;285(14):10786-96 177 Citations |
| 1 | Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis. (Hill MN, McLaughlin RJ, Morrish AC, Viau V, Floresco SB, Hillard CJ, Gorzalka BB) Neuropsychopharmacology 2009 Dec;34(13):2733-45 247 Citations |
| 2 | D2 dopamine receptor activation facilitates endocannabinoid-mediated long-term synaptic depression of GABAergic synaptic transmission in midbrain dopamine neurons via cAMP-protein kinase A signaling. (Pan B, Hillard CJ, Liu QS) J Neurosci 2008 Dec 24;28(52):14018-30 111 Citations |
| 1 | Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists. (Fioravanti B, De Felice M, Stucky CL, Medler KA, Luo MC, Gardell LR, Ibrahim M, Malan TP Jr, Yamamura HI, Ossipov MH, King T, Lai J, Porreca F, Vanderah TW) J Neurosci 2008 Nov 05;28(45):11593-602 76 Citations |
| 1 | First-row transition-metal complexes of a new pentadentate ligand, alpha,alpha,alpha',alpha'-tetra(pyrazolyl)lutidine. (Morin TJ, Bennett B, Lindeman SV, Gardinier JR) Inorg Chem 2008 Sep 01;47(17):7468-70 21 Citations |
| 2 | Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619. (Hillard CJ, Ho WS, Thompson J, Gauthier KM, Wheelock CE, Huang H, Hammock BD) Br J Pharmacol 2007 Nov;152(5):691-8 26 Citations |
| 1 | Celecoxib toxicity is cell cycle phase specific. (Bock JM, Menon SG, Sinclair LL, Bedford NS, Goswami PC, Domann FE, Trask DK) Cancer Res 2007 Apr 15;67(8):3801-8 37 Citations |
| 1 | Relative non-steroidal anti-inflammatory drug (NSAID) antiproliferative activity is mediated through p21-induced G1 arrest and E2F inhibition. (Bock JM, Menon SG, Goswami PC, Sinclair LL, Bedford NS, Domann FE, Trask DK) Mol Carcinog 2007 Oct;46(10):857-64 18 Citations |
| 1 | Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward. (Rademacher DJ, Hillard CJ) Prog Neuropsychopharmacol Biol Psychiatry 2007 Apr 13;31(3):633-41 71 Citations |
| 1 | Involvement of the endocannabinoid system in the ability of long-term tricyclic antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal axis. (Hill MN, Ho WS, Sinopoli KJ, Viau V, Hillard CJ, Gorzalka BB) Neuropsychopharmacology 2006 Dec;31(12):2591-9 108 Citations |
| 2 | Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. (Carrier EJ, Auchampach JA, Hillard CJ) Proc Natl Acad Sci U S A 2006 May 16;103(20):7895-900 386 Citations |
| 1 | Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. (Patel S, Roelke CT, Rademacher DJ, Hillard CJ) Eur J Neurosci 2005 Feb;21(4):1057-69 258 Citations |
| 1 | Celecoxib and radiation therapy in non-small-cell lung cancer. (Gore E) Oncology (Williston Park) 2004 Dec;18(14 Suppl 14):10-4 23 Citations |
| 1 | Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. (Muthian S, Rademacher DJ, Roelke CT, Gross GJ, Hillard CJ) Neuroscience 2004;129(3):743-50 128 Citations |
| 1 | Role of cyclooxygenase-2 in cytokine-induced beta-cell dysfunction and damage by isolated rat and human islets. (Heitmeier MR, Kelly CB, Ensor NJ, Gibson KA, Mullis KG, Corbett JA, Maziasz TJ) J Biol Chem 2004 Dec 17;279(51):53145-51 42 Citations |
| 1 | Rethinking the toxic methanol level. (Kostic MA, Dart RC) J Toxicol Clin Toxicol 2003;41(6):793-800 49 Citations |
| 1 | Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. (Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, Maxwell C, Palmisano J, Keaney JF Jr, Morrow JD, Vita JA) Hypertension 2003 Sep;42(3):310-5 146 Citations |
| 1 | Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. (Rademacher DJ, Patel S, Hopp FA, Dean C, Hillard CJ, Seagard JL) Am J Physiol Heart Circ Physiol 2003 May;284(5):H1570-6 31 Citations |
| 2 | The CB1 receptor antagonist SR141716 enhances stimulus-induced activation of the primary somatosensory cortex of the rat. (Patel S, Gerrits R, Muthian S, Greene AS, Hillard CJ) Neurosci Lett 2002 Dec 25;335(2):95-8 15 Citations |
| 1 | Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. (Plaxe SC, Blessing JA, Husseinzadeh N, Webster KD, Rader JS, Dunton CJ) Gynecol Oncol 2002 Feb;84(2):241-4 19 Citations |
| 1 | Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. (Patel S, Hillard CJ) J Pharmacol Exp Ther 2001 May;297(2):629-37 76 Citations |
| 1 | Protein-tyrosine kinase Pyk2 mediates endothelin-induced p38 MAPK activation in glomerular mesangial cells. (Sorokin A, Kozlowski P, Graves L, Philip A) J Biol Chem 2001 Jun 15;276(24):21521-8 66 Citations |
| 1 | Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. (Tyler K, Hillard CJ, Greenwood-Van Meerveld B) Eur J Pharmacol 2000 Dec 08;409(2):207-11 57 Citations |
| 1 | Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. (Hillard CJ, Muthian S, Kearn CS) FEBS Lett 1999 Oct 08;459(2):277-81 92 Citations |
| 1 | Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. (Kearn CS, Greenberg MJ, DiCamelli R, Kurzawa K, Hillard CJ) J Neurochem 1999 Jun;72(6):2379-87 106 Citations |
| 2 | N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. (Pratt PF, Hillard CJ, Edgemond WS, Campbell WB) Am J Physiol 1998 Jan;274(1):H375-81 110 Citations |
| 1 | Adjunctive therapy (whole body hyperthermia versus lonidamine) to total body irradiation for the treatment of favorable B-cell neoplasms: a report of two pilot clinical trials and laboratory investigations. (Robins HI, Longo WL, Steeves RA, Cohen JD, Schmitt CL, Neville AJ, O'Keefe S, Lagoni R, Riggs C) Int J Radiat Oncol Biol Phys 1990 Apr;18(4):909-20 29 Citations |
| 1 | Phase I trial of lonidamine with whole body hyperthermia in advanced cancer. (Robins HI, Longo WL, Lagoni RK, Neville AJ, Hugander A, Schmitt CL, Riggs C) Cancer Res 1988 Nov 15;48(22):6587-92 29 Citations |
